PIMR and Pulmonary Vascular Disease
The Pulmonary Index of Microcirculatory Resistance: a Novel Hemodynamic Index for Invasively Assessing the Pulmonary Vasculature
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Rushi Parikh, MD
- Phone Number: 310-825-9011
- Email: RParikh@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥18 years old
- Able to provide informed written consent.
- Patients with 1) advanced lung disease requiring standard-of-care bilateral heart catheterization as part of lung transplant evaluation in whom mPAP < 20 mmHg on RHC, or 2) PAH/CTEPH (i.e. pre-capillary PH) undergoing standard-of-care bilateral heart catheterization as part of their work-up/treatment
Exclusion Criteria:
- Contraindicated to undergo fluoroscopy and/or coronary angiography (e.g. pregnancy)
- Chronic kidney disease (serum creatinine ≥ 2.0 mg/dL)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Controls
10 patients without pulmonary hypertension (mean PA pressure less than 20 mmHg on RHC)
|
PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
PIMR of the right and left pulmonary arteries will be obtained.
Other Names:
|
|
PAH
10 patients with PAH
|
RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
Other Names:
PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
PIMR of the right and left pulmonary arteries will be obtained.
Other Names:
OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery.
OCT of the right and left pulmonary arteries will be performed.
|
|
CTEPH
10 patients with CTEPH
|
RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
Other Names:
PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
PIMR of the right and left pulmonary arteries will be obtained.
Other Names:
OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery.
OCT of the right and left pulmonary arteries will be performed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary Index of Microcirculatory Resistance (PIMR)
Time Frame: Baseline
|
PressureWire advanced to distal third of segmental pulmonary artery (PA) for measurement of pulmonary hemodynamics.
The derivation of IMR involves the application of Ohm's law (V=IR) to the coronary microcirculatory circuit, where the relationship between resistance (R) = IMR, voltage (V) = pressure (P), and current (I) = flow (Q) can be expressed as follows: IMR = ∆P/Q.
∆P = the change in pressure across the microvasculature (mean distal coronary artery pressure [Pd] - coronary venous pressure (Pv); Pv is typically disregarded because it is negligible relative to Pd.
Based on the principles of thermodilution, flow is inversely proportion to mean transit time (Q ~ 1/Tmn).
Lastly, the minimal achievable resistance occurs during maximal hyperemic flow when all available microvessels have theoretically been recruited.
Hence, the calculation of IMR simplifies to the following formula: IMR = Pd (pulmonary artery) x TmnHyp.
|
Baseline
|
|
Right Ventricle Index of Microcirculatory Resistance (RV-IMR)
Time Frame: Baseline
|
PressureWire advanced to distal third of acute marginal branch of the right coronary artery (RCA) for measurement of pulmonary hemodynamics.
The derivation of IMR involves the application of Ohm's law (V=IR) to the coronary microcirculatory circuit, where the relationship between resistance (R) = IMR, voltage (V) = pressure (P), and current (I) = flow (Q) can be expressed as follows: IMR = ∆P/Q.
∆P = the change in pressure across the microvasculature (mean distal coronary artery pressure [Pd] - coronary venous pressure (Pv); Pv is typically disregarded because it is negligible relative to Pd.
Based on the principles of thermodilution, flow is inversely proportion to mean transit time (Q ~ 1/Tmn).
Lastly, the minimal achievable resistance occurs during maximal hyperemic flow when all available microvessels have theoretically been recruited.
Hence, the calculation of IMR simplifies to the following formula: IMR = Pd (RCA marginal branch) x TmnHyp.
|
Baseline
|
|
OCT-derived pulmonary artery wall thickness
Time Frame: Baseline
|
A Dragonfly Optis OCT catheter (Abbott) will be advanced over the PressureWireX to the distal left lower lobe segmental pulmonary artery (luminal diameter < 5 mm and minimal length of 50 mm).
OCT images of the pulmonary artery will be recorded via automatic pullback and analyzed offline in a blinded manner.
|
Baseline
|
|
OCT-derived thickness-diameter ratio
Time Frame: Baseline
|
A Dragonfly Optis OCT catheter (Abbott) will be advanced over the PressureWireX to the distal left lower lobe segmental pulmonary artery (luminal diameter < 5 mm and minimal length of 50 mm).
OCT images of the pulmonary artery will be recorded via automatic pullback and analyzed offline in a blinded manner.
|
Baseline
|
|
OCT-derived wall-area ratio
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Rushi Parikh, MD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB#22-001643
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.